Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.
about
Mutant p53: One, No One, and One Hundred ThousandTargeting Oncogenic Mutant p53 for Cancer TherapyThe Contrived Mutant p53 Oncogene - Beyond Loss of FunctionsThe rebel angel: mutant p53 as the driving oncogene in breast cancer.Ultra-Rare Syndromes: The Example of Rubinstein-Taybi SyndromeSFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancerArsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligaseThe histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibitionPhase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.Ginsenoside Rg3 Inhibits Constitutive Activation of NF-κB Signaling in Human Breast Cancer (MDA-MB-231) Cells: ERK and Akt as Potential Upstream Targets.Mechanism of N-Acylthiourea-mediated activation of human histone deacetylase 8 (HDAC8) at molecular and cellular levels.Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cellsPreclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.TAp73 protein stability is controlled by histone deacetylase 1 via regulation of Hsp90 chaperone function.Modeling the Etiology of p53-mutated Cancer Cells.The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β.Plasticity of lung cancer stem-like cells is regulated by the transcription factor HOXA5 that is induced by oxidative stress.HDAC inhibitor-based therapies: can we interpret the code?Mutant p53 in cancer: new functions and therapeutic opportunities.Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 statusTargeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases.Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.Histone deacetylases function as a novel potential therapeutic target for cancer.Neomorphic mutations create therapeutic challenges in cancer.DEC1 coordinates with HDAC8 to differentially regulate TAp73 and ΔNp73 expression.The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma.HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha.Structure-Based Identification of HDAC8 Non-histone SubstratesNAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity.Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and PromisesHistone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines.Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53.Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery.Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.
P2860
Q26770576-7903C3A1-D3D9-4BE4-8E2A-02C3F2CC8A07Q26770856-2151B588-CE20-46BE-AFB6-EEB7AF0D91C7Q26772237-0EA56FD5-0052-431B-8410-ADE50DB01284Q27686765-D28A60C0-ABED-4B01-9D22-2329979E5152Q28080220-255C0454-65F7-4D79-8207-3832D1815B2EQ28277902-29E662DB-6C72-403A-A8D1-2B0B2B90305DQ28541801-F3AB47BF-D1A7-4F21-B5B2-B7906098DD05Q28542639-B331C04F-63B6-4D5C-9C8C-820538F296CEQ33420276-94E09B2D-EDD8-4732-9D29-D64F8807E4E9Q34305486-52B543D0-B0DC-4400-AE41-C70FCBEAD683Q35173031-B22313D0-CA89-45DC-805B-140259D68A71Q36094595-B14BAF7E-525B-4A65-8289-F30B89D9054BQ36288249-1DFFF5FB-E74D-4AC5-BEFF-290FEDAA4780Q36562253-91794147-B2E2-4CEC-8224-6BB8DE5C2EBDQ36685194-03573633-48B7-4927-9E2C-02151E603291Q36876179-43008D38-03B6-4C40-925F-02591EBAA037Q36926692-4D235B82-3B71-45A9-A5FB-DA20A4B27DCFQ37105454-CE761B72-7459-442B-9623-21C875A82FF4Q37580362-AB29C068-41F9-4F0C-A27D-EA66E9ECEA4FQ38058971-BF48BA4E-3B99-44AC-9579-3D92CD230BF7Q38197826-1735787F-7E4E-48BB-97A2-1BD5CD3B4495Q38751430-C05F4513-3851-4E52-BE24-327858F55923Q38826740-41BBE0F9-E002-4C27-99EE-AF69AF200819Q38862949-5A04A79D-BDF5-4519-B382-092D2269618DQ38908331-D2C9FB21-CBD9-436E-97F2-2625CBA64AE9Q39007820-05613388-A4FC-42EA-A718-002189F7CF03Q39036140-497188DD-D01D-46F5-A3E4-0A7F5699A923Q39090052-77910536-F5A0-4931-8FD2-83F2D2ED2B00Q39307665-CB6CAD70-96FB-4A72-BA03-99A87A67FBEBQ39926027-A6B82762-9BE3-4B8A-AB0C-673B29B0DB13Q41347745-463D43B4-4375-47CA-807D-5B69BB128AD8Q41496911-ED297E19-E314-4797-B4D1-9EF88ADCD0BBQ41585790-26C52DEC-668E-46A4-ACC6-40992DE849CAQ41664067-D43F38F0-8650-4093-A327-66E9EA6620F2Q44948239-83530771-DD71-402E-8213-959A784BFED0Q45948898-69819E84-0924-4056-ACED-018D29713B49Q46038047-6B1CF7AE-8AF6-440A-B7AE-BF5CFE8B96B8Q47136872-0F5D2A6B-6216-42B4-858E-2C27B1A9AFF9Q47357144-B5FBF220-59FB-49A3-92A0-AFAABFFC72C0Q47633998-2BB76866-D476-4ED1-8C4C-60B64EFF3227
P2860
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Histone deacetylase inhibitors ...... ion via histone deacetylase 8.
@ast
Histone deacetylase inhibitors ...... ion via histone deacetylase 8.
@en
type
label
Histone deacetylase inhibitors ...... ion via histone deacetylase 8.
@ast
Histone deacetylase inhibitors ...... ion via histone deacetylase 8.
@en
prefLabel
Histone deacetylase inhibitors ...... ion via histone deacetylase 8.
@ast
Histone deacetylase inhibitors ...... ion via histone deacetylase 8.
@en
P2093
P2860
P356
P1433
P1476
Histone deacetylase inhibitors ...... ion via histone deacetylase 8.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2012.81
P407
P577
2012-03-05T00:00:00Z
P5875
P6179
1012645003